Inhibitors of the renin-angiotensin system as new antihypertensive agents.

Inhibitors of the renin-angiotensin system as new antihypertensive agents. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Inhibitors of the renin-angiotensin system as new antihypertensive agents. Abstract Text:

M J Antonaccio,

There are several approaches for interfering with the renin-angiotensin system. Antibodies against renin and angiotensins I and II (AI and AII) have not been consistently successful in the past, probably because of nonspecific effects; however, recent purification of renin now makes this approach more promising. Renin inhibitors include pepstatin and analogs, lipids and phospholipids, and renin-substrate analogs. Pepstatin and analogs are the most potent and specific but they are not orally active. The phospholipids are the most effective in vivo but their specificity is yet to be established. Renin-substrate analogs have been developed that have biologically significant effects but are not orally active. Some of the most potent and specific agents available for interfering with the renin-angiotensin system are the AII receptor antagonists. While these compounds effectively prevent the actions of AII, they suffer from several severe deficiencies: partial agonist activity, short duration of action, and lack of oral activity. The recent development of angiotensin-converting enzyme (ACE) inhibitors that are orally active has provided the greatest degree of clinical success for inhibitors of the renin-angiotensin system and, consequently, the impetus to develop still better compounds. Captopril (SQ 14,225) is the prototype ACE inhibitor, being highly potent and specific with no other demonstrated pharmacological activity. Captopril is effective in all forms of human and animal models of hypertension except mineralocorticoid hypertension, which requires concomitant diuretic therapy. Because ACE is the same enzyme as kininase II, the enzyme that degrades kinins, the possibility exists that kinins are involved in the cardiovascular action of captopril, although this prospect is unlikely.

Inhibitors of the renin-angiotensin system as new antihypertensive agents. Publishing Authors By Initials

MJ Antonaccio,

For similar peptides: oligopeptides: teprotide research abstracts see: peptides: oligopeptides: teprotide research

PUBMED ID PMID:

MEDLINE DATE:

Inhibitors of the renin-angiotensin system as new antihypertensive agents. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Clinical and experimental hypertension. Part A, Th

VOLUME: 4

Page Numbers: 27-46

Journal Abbreviation:

ISSN: 0730-0077

DAY: 12

MONTH: 02

YEAR: 1982

Inhibitors of the renin-angiotensin system as new antihypertensive agents. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8207790

Inhibitors of the renin-angiotensin system as new antihypertensive agents. Keywords Mesh Terms:

KEYWORDS: Teprotide

MESH TERMS: drug effects

Chemical & Substance for Abstract: Inhibitors of the renin-angiotensin system as new antihypertensive agents. Information

Substance Name: Renin

Registry Number: EC 3.4.23.15

Grant and Affiliation Information for Inhibitors of the renin-angiotensin system as new antihypertensive agents.

AFFILIATION:

Country: UNITED STATES

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Clin Exp Hypertens A

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Inhibitors of the renin-angiotensin system as new antihypertensive agents Related Publications

• Considerations for developing an antiarrhythmic agent: a perspective from the pharmaceutical industry.
• Inhibitors of the renin-angiotensin system as new antihypertensive agents.